New hope for chinese men with tough prostate cancer: targeted drug takes on standard care
NCT ID NCT05457257
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares the targeted drug olaparib to two standard hormone therapies (enzalutamide or abiraterone) in Chinese men with advanced prostate cancer that has stopped responding to hormone treatment and who have BRCA1/2 gene mutations. The goal is to see if olaparib can delay cancer growth better than the usual options. About 43 men will participate, and the study tracks how long their cancer stays under control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Beijing, 100050, China
-
Research Site
Bengbu, 233004, China
-
Research Site
Changsha, 410008, China
-
Research Site
Changsha, 410013, China
-
Research Site
Chengdu, 610000, China
-
Research Site
Chongqing, 408099, China
-
Research Site
Fuzhou, 350005, China
-
Research Site
Guangzhou, 510060, China
-
Research Site
Guangzhou, 510180, China
-
Research Site
Hangzhou, 310003, China
-
Research Site
Hangzhou, 310009, China
-
Research Site
Hangzhou, 310014, China
-
Research Site
Hefei, 230601, China
-
Research Site
Jiaxing, 314001, China
-
Research Site
Jinan, 250012, China
-
Research Site
Jinan, 250021, China
-
Research Site
Jining, 272029, China
-
Research Site
Kunming, 650101, China
-
Research Site
Lanzhou, 730030, China
-
Research Site
Linyi, 276000, China
-
Research Site
Nanchang, 330006, China
-
Research Site
Nantong, 226361, China
-
Research Site
Ningbo, 315010, China
-
Research Site
Shanghai, 200002, China
-
Research Site
Shanghai, 200032, China
-
Research Site
Shenyang, 110004, China
-
Research Site
Suzhou, 215004, China
-
Research Site
Taiyuan, 030000, China
-
Research Site
Tianjin, 300060, China
-
Research Site
Wanzhou, 404000, China
-
Research Site
Wuhan, 430022, China
-
Research Site
Wuxi, 214002, China
-
Research Site
Wuxi, 214023, China
-
Research Site
Xi'an, 710077, China
-
Research Site
Zhengzhou, 450052, China